Core Viewpoint - AIM ImmunoTech Inc. has received a patent from the Japan Patent Office for the use of Ampligen in combination with checkpoint inhibitors for cancer treatment, enhancing its international market protection and potential for revenue growth [1][2]. Group 1: Patent and Market Implications - The Japan patent strengthens AIM's intellectual property portfolio in a significant oncology market, expiring on December 20, 2039, and enhances exclusivity for combination therapies targeting high-need cancer indications [2][4]. - The patent claims cover a wide range of cancer types, including pancreatic, skin, colorectal, ovarian, melanoma, breast, head and neck, bladder, renal cell carcinoma, and lung cancer, along with specific dosing regimens and administration routes [3]. Group 2: Clinical Development and Collaborations - AIM is advancing its clinical pipeline with Ampligen in combination with AstraZeneca's durvalumab for metastatic pancreatic cancer, showing promising results in Progression-Free Survival and Overall Survival [5]. - A Phase 2 study with Merck Sharp & Dohme LLC combining Ampligen with Keytruda for advanced recurrent ovarian cancer has been completed, with final data expected soon [6]. Group 3: Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen being a first-in-class investigational drug that acts as a TLR3 agonist [7].